These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8839171)

  • 1. Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application.
    Zitvogel L; Lotze MT
    Res Immunol; 1995; 146(7-8):628-38. PubMed ID: 8839171
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of IL12 as an anti-tumour agent: current status and future directions.
    Brunda MJ
    Res Immunol; 1995; 146(7-8):622-28. PubMed ID: 8839170
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumor activities of IL-12 and mechanisms of action.
    Shurin MR; Esche C; Péron JM; Lotze MT
    Chem Immunol; 1997; 68():153-74. PubMed ID: 9329221
    [No Abstract]   [Full Text] [Related]  

  • 4. A sequence of cellular and molecular events involved in IL12-induced tumour regression.
    Fujiwara H; Zou JP; Herrmann S; Hamaoka T
    Res Immunol; 1995; 146(7-8):638-44. PubMed ID: 8839172
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mIL12) subunits in a rat medullary thyroid carcinoma model.
    Zhang R; DeGroot LJ
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):687-94. PubMed ID: 10848872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL12 as an adjuvant for vaccines designed to prevent infection and immunopathology by schistosomes.
    Wynn TA; Sher A
    Res Immunol; 1995; 146(7-8):582-90. PubMed ID: 8839165
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-12: biological properties and clinical application.
    Del Vecchio M; Bajetta E; Canova S; Lotze MT; Wesa A; Parmiani G; Anichini A
    Clin Cancer Res; 2007 Aug; 13(16):4677-85. PubMed ID: 17699845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-12: basic principles and clinical applications.
    Trinchieri G; Scott P
    Curr Top Microbiol Immunol; 1999; 238():57-78. PubMed ID: 10087650
    [No Abstract]   [Full Text] [Related]  

  • 9. Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy.
    Cutrera J; King G; Jones P; Kicenuik K; Gumpel E; Xia X; Li S
    J Cell Mol Med; 2015 Mar; 19(3):664-75. PubMed ID: 25628149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of IL-12 to cytokine therapy and gene therapy for tumors.
    Nishimura T; Watanabe K; Yahata T; Uede T; Saiki I; Herrmann SH; Kobayashi M; Habu S
    Ann N Y Acad Sci; 1996 Oct; 795():375-8. PubMed ID: 8958959
    [No Abstract]   [Full Text] [Related]  

  • 11. Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice.
    Nemeckova S; Sroller V; Hainz P; Krystofova J; Smahel M; Kutinova L
    Int J Mol Med; 2003 Nov; 12(5):789-96. PubMed ID: 14533011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-12. Biologic activity, therapeutic utility, and role in disease.
    Hendrzak JA; Brunda MJ
    Lab Invest; 1995 Jun; 72(6):619-37. PubMed ID: 7783421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of interleukin-12 receptor on peripheral blood mononuclear cells and HLA class I, HLA class II or ICAM-1 on melanoma cells by B7.1 and interleukin-12: a mechanism for immunostimulatory impact of melanoma cells adenovirally transfected with B7.1 and IL12?
    Yue FY; Cao L; Hemmi S; Geertsen R; Laine E; Burg G; Dummer R
    Melanoma Res; 2000 Aug; 10(4):313-22. PubMed ID: 10985665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12, an emerging anti-tumour cytokine.
    Hiscox S; Jiang WG
    In Vivo; 1997; 11(2):125-32. PubMed ID: 9179604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
    Dabrowska A; Giermasz A; Gołab J; Jakóbisiak M
    Neoplasma; 2001; 48(5):358-61. PubMed ID: 11845979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.
    Péron JM; Bureau C; Gourdy P; Lulka H; Souque A; Calippe B; Selves J; Al Saati T; Bernad J; Cordelier P; Couderc B; Pradayrol L; Pipy B; Buscail L; Vinel JP
    Gut; 2007 Jan; 56(1):107-14. PubMed ID: 16891358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12: murine models of a potent antitumor agent.
    Brunda MJ; Luistro L; Rumennik L; Wright RB; Wigginton JM; Wiltrout RH; Hendrzak JA; Palleroni AV
    Ann N Y Acad Sci; 1996 Oct; 795():266-74. PubMed ID: 8958938
    [No Abstract]   [Full Text] [Related]  

  • 19. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 20. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
    Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
    Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.